FOLR2 and neoplasm: We, therefore, postulate that the development of a staged clinical regimen that first pre-conditions the TME by a combination of lympho-depleting chemotherapy and specific depletion of immunosuppressive FRβ+ TAMs and is followed by administration of a conventional tumor-targeted CAR-T cell product may enhance outcomes in patients with most solid tumors.